The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barel, M.
Right arrow Articles by Frade, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barel, M.
Right arrow Articles by Frade, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
The Journal of Immunology, 2001, 166: 3167-3173.
Copyright © 2001 by The American Association of Immunologists

Activation of the EBV/C3d Receptor (CR2, CD21) on Human B Lymphocyte Surface Triggers Tyrosine Phosphorylation of the 95-kDa Nucleolin and Its Interaction with Phosphatidylinositol 3 Kinase1

Monique Barel, Muriel Le Romancer and Raymond Frade2

Immunochimie des Régulations Cellulaires et des Interactions Virales, Centre Institut National de la Santé et de la Recherche Médicale, Paris, France

We previously demonstrated that CR2 activation on human B lymphocyte surface triggered tyrosine phosphorylation of a p95 component and its interaction with p85 subunit of phosphatidylinositol 3' (PI 3) kinase. Despite identical molecular mass of 95 kDa, this tyrosine phosphorylated p95 molecule was not CD19, the proto-oncogene Vav, or the adaptator Gab1. To identify this tyrosine phosphorylated p95 component, we first purified it by affinity chromatography on anti-phosphotyrosine mAb covalently linked to Sepharose 4B, followed by polyacrylamide gel electrophoresis. Then, the isolated 95-kDa tyrosine phosphorylated band was submitted to amino acid analysis by mass spectrometry; the two different isolated peptides were characterized by amino acid sequences 100% identical with two different domains of nucleolin, localized between aa 411–420 and 611–624. Anti-nucleolin mAb was used to confirm the antigenic properties of this p95 component. Functional studies demonstrated that CR2 activation induced, within a brief span of 2 min, tyrosine phosphorylation of nucleolin and its interaction with Src homology 2 domains of the p85 subunit of PI 3 kinase and of 3BP2 and Grb2, but not with Src homology 2 domains of Fyn and Gap. These properties of nucleolin were identical with those of the p95 previously described and induced by CR2 activation. Furthermore, tyrosine phosphorylation of nucleolin was also induced in normal B lymphocytes by CR2 activation but neither by CD19 nor BCR activation. These data support that tyrosine phosphorylation of nucleolin and its interaction with PI 3 kinase p85 subunit constitute one of the earlier steps in the specific intracellular signaling pathway of CR2.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. C. Girvan, Y. Teng, L. K. Casson, S. D. Thomas, S. Juliger, M. W. Ball, J. B. Klein, W. M. Pierce Jr., S. S. Barve, and P. J. Bates
AGRO100 inhibits activation of nuclear factor-{kappa}B (NF-{kappa}B) by forming a complex with NF-{kappa}B essential modulator (NEMO) and nucleolin.
Mol. Cancer Ther., July 1, 2006; 5(7): 1790 - 1799.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. P. Huddleson, N. Ahmad, and J. B. Lingrel
Up-regulation of the KLF2 Transcription Factor by Fluid Shear Stress Requires Nucleolin
J. Biol. Chem., June 2, 2006; 281(22): 15121 - 15128.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Huang, H. Chen, L. Hutt-Fletcher, R. F. Ambinder, and S. D. Hayward
Lytic Viral Replication as a Contributor to the Detection of Epstein-Barr Virus in Breast Cancer
J. Virol., December 15, 2003; 77(24): 13267 - 13274.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.